Risk factors of SARS-CoV-2 infection in cancer patients pre- and post-vaccination
暂无分享,去创建一个
A. Assiri | F. Alhumaydhi | Abdulrhman Aljouie | S. Alsagaby | N. Alharbi | M. Bosaeed | K. Alshammari | N. K. Alharbi | Faisal S Alsubaie | Faisal S. Alsubaie | Kanan Alshammari
[1] M. Preusser,et al. SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria , 2022, Wiener klinische Wochenschrift.
[2] K. Decker,et al. Evaluating the impact of the COVID-19 pandemic on cancer screening in a central Canadian province , 2022, Preventive Medicine.
[3] G. Siasos,et al. Charting the Unknown Association of COVID-19 with Thyroid Cancer, Focusing on Differentiated Thyroid Cancer: A Call for Caution , 2021, Cancers.
[4] Jin-fang Xu,et al. Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines , 2021, Cell discovery.
[5] S. Mir,et al. Haematological and radiological-based prognostic markers of COVID-19 , 2021, Journal of Infection and Public Health.
[6] N. Arber,et al. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients , 2021, Journal of the National Cancer Institute.
[7] S. Olatunji,et al. Comorbidities and Risk Factors for Severe Outcomes in COVID-19 Patients in Saudi Arabia: A Retrospective Cohort Study , 2021, Journal of multidisciplinary healthcare.
[8] T. Spektor,et al. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma , 2021, Leukemia.
[9] S. Wen,et al. One‐year mortality and consequences of COVID‐19 in cancer patients: A cohort study , 2021, IUBMB life.
[10] E. Sawyer,et al. COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients , 2021, Cancers.
[11] E. Chamorey,et al. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors , 2021, Annals of Oncology.
[12] M. Malim,et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study , 2021, The Lancet Oncology.
[13] M. Dimopoulos,et al. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose , 2021, Blood.
[14] M. Rotondi,et al. Thyroid sequelae of COVID-19: a systematic review of reviews , 2021, Reviews in Endocrine and Metabolic Disorders.
[15] Mohammed Aljuaid,et al. Cardiovascular Risk Factors Among Patients Infected with COVID-19 in Saudi Arabia , 2021, Vascular health and risk management.
[16] G. Ursin,et al. COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway , 2021, Frontiers in Oncology.
[17] N. Fernández,et al. Early prediction keys for COVID-19 cases progression: A meta-analysis , 2021, Journal of Infection and Public Health.
[18] N. Al-Daghri,et al. Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study , 2020, Cardiovascular Diabetology.
[19] H. Tayebi-Khosroshahi,et al. Risk Factors for COVID-19. , 2020, Le infezioni in medicina.
[20] N. Al-Daghri,et al. Prevalence of diabetes, management and outcomes among Covid-19 adult patients admitted in a specialized tertiary hospital in Riyadh, Saudi Arabia , 2020, Diabetes Research and Clinical Practice.
[21] Nathanael R. Fillmore,et al. Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study , 2020, Journal of the National Cancer Institute.
[22] C. Akdis,et al. Risk factors for severe and critically ill COVID‐19 patients: A review , 2020, Allergy.
[23] D. Kerr,et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study , 2020, The Lancet Oncology.
[24] P. Lovat,et al. Reduction in skin cancer diagnoses in the UK during the COVID‐19 pandemic , 2020, Clinical and experimental dermatology.
[25] F. Pitoia,et al. Thyroid cancer in the Era of COVID-19 , 2020, Endocrine.
[26] R. Gale,et al. Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission , 2020, Leukemia.
[27] E. Robilotti,et al. Determinants of COVID-19 disease severity in patients with cancer , 2020, Nature Medicine.
[28] Nazar Zaki,et al. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[29] D. Ma,et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis , 2020, Journal of Hematology & Oncology.
[30] A. Assiri,et al. Clinical characteristics of COVID-19 in Saudi Arabia: A national retrospective study , 2020, Journal of Infection and Public Health.
[31] Sun-Hee Park,et al. Outcomes of COVID-19 among Patients on In-Center Hemodialysis: An Experience from the Epicenter in South Korea , 2020, Journal of clinical medicine.
[32] Zhiquan Hu,et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.
[33] Jun Yu Li,et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.
[34] Alokkumar Jha,et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.
[35] M. Gleeson,et al. Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London , 2020, Frontiers in Oncology.
[36] H. Alwafi,et al. Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia , 2020, medRxiv.
[37] A. Vincent-Salomon,et al. COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area , 2020, Breast Cancer Research.
[38] S. Kalnicki,et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System , 2020, Cancer discovery.
[39] E. Rodríguez‐Suárez,et al. High prevalence of asymptomatic COVID-19 in hemodialysis. Daily learning during first month of COVID-19 pandemic , 2020, Nefrología (English Edition).
[40] M. Santillana,et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.
[41] Geltrude Mingrone,et al. Practical recommendations for the management of diabetes in patients with COVID-19 , 2020, The Lancet Diabetes & Endocrinology.
[42] O. Al-Quteimat,et al. The Impact of the COVID-19 Pandemic on Cancer Patients , 2020, American journal of clinical oncology.
[43] C. Booth,et al. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic , 2020, Nature Reviews Clinical Oncology.
[44] T. Ikizler. COVID-19 and Dialysis Units: What Do We Know Now and What Should We Do? , 2020, American Journal of Kidney Diseases.
[45] Rui Ji,et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.
[46] Ritesh Gupta,et al. Clinical considerations for patients with diabetes in times of COVID-19 epidemic , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[47] Ruchong Chen,et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.
[48] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[49] A. Fard-Esfahani,et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma , 2014, Nuclear medicine communications.
[50] Stephanie L. Lee. Complications of radioactive iodine treatment of thyroid carcinoma. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[51] S. Larson,et al. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. , 2009, Thyroid : official journal of the American Thyroid Association.
[52] S. Chow. Side Effects of High-dose Radioactive Iodine for Ablation or Treatment of Differentiated Thyroid Carcinoma , 2005 .